Saturday, July 20, 2024 6:10:46 PM
You are one sick puppy. In this industry they pull in the best experts when reviewing drugs, that committee will no doubt also have competitors on it as well. Dr. Mulholland was only called in when Dr. Liau took sick with covid while in the UK so she couldn't possibly appear in the US, but otherwise he's not been a major advocate for NWBO. Yes, he's a subject matter expert, and yes he does have familiarity with the vaccine, but who do you want on such a panel, people who know nothing about what they're discussing.
I have no idea who else is on the panel, but would NWBO be able to disqualify anyone on it who at any time did something with a product which could be considered a competitor, I don't think so. There is no doubt that people who truly have the expertise to properly sit on a panel of experts will have experience with many products, the question is, is the product they're reviewing a tool that they'd want to have in their toolbox if they were treating patients with the disease. I believe Drs. will choose to have more than one product available, even if they're only associated with one of them.
Gary
I have no idea who else is on the panel, but would NWBO be able to disqualify anyone on it who at any time did something with a product which could be considered a competitor, I don't think so. There is no doubt that people who truly have the expertise to properly sit on a panel of experts will have experience with many products, the question is, is the product they're reviewing a tool that they'd want to have in their toolbox if they were treating patients with the disease. I believe Drs. will choose to have more than one product available, even if they're only associated with one of them.
Gary
Bullish
Recent NWBO News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
